| 1. | Chen W. Cancer statistics: updated cancer burden in China. Chin J Cancer Res, 2015, 27(1): 1. | 
				                                                        
				                                                            
				                                                                | 2. | Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin, 2011, 61(2): 69-90. | 
				                                                        
				                                                            
				                                                                | 3. | 中華人民共和國國家衛生和計劃生育委員會. 原發性肝癌診療規范 (2017 年版). 傳染病信息, 2017, 16(3): 705-720. | 
				                                                        
				                                                            
				                                                                | 4. | Dimitroulis D, Damaskos C, Valsami S, et al. From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world. World J Gastroenterol, 2017, 23(29): 5282-5294. | 
				                                                        
				                                                            
				                                                                | 5. | Bruix J, Hessheimer AJ, Forner A, et al. New aspects of diagnosis and therapy of hepatocellular carcinoma. Oncogene, 2006, 25(27): 3848-3856. | 
				                                                        
				                                                            
				                                                                | 6. | Aravalli RN, Steer CJ, Cressman EN. Molecular mechanisms of hepatocellular carcinoma. Hepatology, 2008, 48(6): 2047-2063. | 
				                                                        
				                                                            
				                                                                | 7. | Zinkin NT, Grall F, Bhaskar K, et al. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clin Cancer Res, 2008, 14(2): 470-477. | 
				                                                        
				                                                            
				                                                                | 8. | Wu Y, Yu J, Ma Y, et al. miR-148a and miR-375 may serve as predictive biomarkers for early diagnosis of laryngeal carcinoma. Oncol Lett, 2016, 12(2): 871-878. | 
				                                                        
				                                                            
				                                                                | 9. | Lin H, Ewing LE, Koturbash I, et al. MicroRNAs as biomarkers for liver injury: Current knowledge, challenges and future prospects. Food Chem Toxicol, 2017, 110: 229-239. | 
				                                                        
				                                                            
				                                                                | 10. | Armand-Labit V, Pradines A. Circulating cell-free microRNAs as clinical cancer biomarkers. Biomol Concepts, 2017, 8(2): 61-81. | 
				                                                        
				                                                            
				                                                                | 11. | Fu Y, Wei X, Tang C, et al. Circulating microRNA-101 as a potential biomarker for hepatitis B virus-related hepatocellular carcinoma. Oncol Lett, 2013, 6(6): 1811-1815. | 
				                                                        
				                                                            
				                                                                | 12. | 於琳, 張開炯, 柴利, 等. 原發性肝癌患者癌組織、血清 miR-202 表達變化及其意義. 山東醫藥, 2017, 57(7): 1-4. | 
				                                                        
				                                                            
				                                                                | 13. | Armengol C, Sarrias MR, Sala M. Hepatocellular carcinoma: Present and future. Med Clin (Barc), 2017 Oct 30. pii: S0025-7753(17)30717-0. doi: 10.1016/j.medcli.2017.08.010. [Epub ahead of print]. | 
				                                                        
				                                                            
				                                                                | 14. | Siddique O, Yoo ER, Perumpail RB, et al. The importance of a multidisciplinary approach to hepatocellular carcinoma. J Multidiscip Healthc, 2017, 10: 95-100. | 
				                                                        
				                                                            
				                                                                | 15. | Huang Z, Huang D, Ni S, et al. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer, 2010, 127(1): 118-126. | 
				                                                        
				                                                            
				                                                                | 16. | Hu Z, Chen X, Zhao Y, et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol, 2010, 28(10): 1721-1726. | 
				                                                        
				                                                            
				                                                                | 17. | Liu AM, Yao TJ, Wang W, et al. Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open, 2012, 2(2): e000825. | 
				                                                        
				                                                            
				                                                                | 18. | Fiorino S, Bacchi-Reggiani ML, Visani M, et al. MicroRNAs as possible biomarkers for diagnosis and prognosis of hepatitis B- and C-related-hepatocellular-carcinoma. World J Gastroenterol, 2016, 22(15): 3907-3936. | 
				                                                        
				                                                            
				                                                                | 19. | 孟凡龍, 莢衛東, 許戈良, 等. 肝癌患者血清 miR-106 b 的表達變化及其臨床意義. 安徽醫科大學學報, 2014, 49(3): 334-337, 338. | 
				                                                        
				                                                            
				                                                                | 20. | Xu J, Wu C, Che X, et al. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog, 2011, 50(2): 136-142. | 
				                                                        
				                                                            
				                                                                | 21. | Zhang Y, Jia Y, Zheng R, et al. Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. Clin Chem, 2010, 56(12): 1830-1838. | 
				                                                        
				                                                            
				                                                                | 22. | Gui J, Tian Y, Wen X, et al. Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies. Clin Sci (Lond), 2011, 120(5): 183-193. | 
				                                                        
				                                                            
				                                                                | 23. | Qu KZ, Zhang K, Li H, et al. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol, 2011, 45(4): 355-360. | 
				                                                        
				                                                            
				                                                                | 24. | Shen S, Lin Y, Yuan X, et al. Biomarker micrornas for diagnosis, prognosis and treatment of hepatocellular carcinoma: a functional survey and comparison. Sci Rep, 2016, 6: 38311. | 
				                                                        
				                                                            
				                                                                | 25. | Meyer-Rochow GY, Jackson NE, Conaglen JV, et al. MicroRNA profiling of benign and malignant pheochromocytomas identifies novel diagnostic and therapeutic targets. Endocr Relat Cancer, 2010, 17(3): 835-846. | 
				                                                        
				                                                            
				                                                                | 26. | 李迎迎, 王森嵩. MiR-483-5p 在食管鱗癌血清和組織中的表達及其調控機理的初步探究. 河南師范大學, 2016. | 
				                                                        
				                                                            
				                                                                | 27. | Patterson EE, Holloway AK, Weng J, et al. MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy. Cancer, 2011, 117(8): 1630-1639. | 
				                                                        
				                                                            
				                                                                | 28. | Yao M, Zhao J, Lu F. Alpha-fetoprotein still is a valuable diagnostic and prognosis predicting biomarker in hepatitis B virus infection-related hepatocellular carcinoma. Oncotarget. 2016; 7(4): 3702-3708. |